Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With <i>ALK</i>/<i>ROS1</i>/<i>RET</i>-Rearranged Lung Cancers.
Harper G HubbelingNoura J ChoudhuryJessica R FlynnZhigang ZhangChristina J FalconValerie W RuschBernard J ParkEtay ZivNarek ShaverdianDaphna Y GelblumAnnemarie F ShepherdCharles B SimoneAbraham Jing-Ching WuDaniel R GomezAlexander E DrilonAndreas RimnerPublished in: JCO precision oncology (2022)
Local therapy for progression on ALK, ROS1, or RET TKIs is associated with clinically meaningful time on continued TKI therapy beyond progression, especially earlier in the course of disease.